Skip to Main Content

Author Details

Christina M??ller-Koop
Institute of Pathology, University Medical Center Hamburg-Eppendorf
2006
83
25
PMIDPaper TitleJournal TitlePublished Year
35941227The prognostic impact of B7-H3 and B7-H4 in head and neck squamous cell carcinoma.J Cancer Res Clin Oncol2023
346259096q deletion is frequent but unrelated to patient prognosis in breast cancer.Breast Cancer2022
35406601Tissue Microarray Analyses Suggest Axl as a Predictive Biomarker in HPV-Negative Head and Neck Cancer.Cancers (Basel)2022
32361874A non-diploid DNA status is linked to poor prognosis in renal cell cancer.World J Urol2021
34547930MUC5AC Expression in Various Tumor Types and Nonneoplastic Tissue: A Tissue Microarray Study on 10â¿¿399 Tissue Samples.Technol Cancer Res Treat2021
34083496Prevalence of proliferating CD8<sup>+</sup> cells in normal lymphatic tissues, inflammation and cancer.Aging (Albany NY)2021
33373033Elevated MUC5AC expression is associated with mismatch repair deficiency and proximal tumor location but not with cancer progression in colon cancer.Med Mol Morphol2021
33045100Chromosome 5 harbors two independent deletion hotspots at 5q13 and 5q21 that characterize biologically different subsets of aggressive prostate cancer.Int J Cancer2021
32534597Chromosome 17p13 deletion is associated with an aggressive tumor phenotype in clear cell renal cell carcinoma.World J Surg Oncol2020
317577388p deletions in renal cell carcinoma are associated with unfavorable tumor features and poor overall survival.Urol Oncol2020
32076485Prevalence and clinical significance of VHL mutations and 3p25 deletions in renal tumor subtypes.Oncotarget2020
31893572Loss of cytoplasmic survivin expression is an independent predictor of poor prognosis in radically operated prostate cancer patients.Cancer Med2020
32677026Secreted Frizzled-Related Protein 4 (SFRP4) Is an Independent Prognostic Marker in Prostate Cancers Lacking TMPRSS2: ERG Fusions.Pathol Oncol Res2020
32241691Chromosomal deletion of 9p21 is linked to poor patient prognosis in papillary and clear cell kidney cancer.Urol Oncol2020
32143573Upregulation of the transcription factor TFAP2D is associated with aggressive tumor phenotype in prostate cancer lacking the TMPRSS2:ERG fusion.Mol Med2020
32545200Mass Spectrometric Comparison of HPV-Positive and HPV-Negative Oropharyngeal Cancer.Cancers (Basel)2020
32377272Upregulation of Phosphatase 1 Nuclear-Targeting Subunit (PNUTS) Is an Independent Predictor of Poor Prognosis in Prostate Cancer.Dis Markers2020
306235095q21 deletion is often heterogeneous in prostate cancer.Genes Chromosomes Cancer2019
31976021Prevalence of Syndecan-1 (CD138) Expression in Different Kinds of Human Tumors and Normal Tissues.Dis Markers2019
31612022Upregulation of SPDEF is associated with poor prognosis in prostate cancer.Oncol Lett2019
31382165Down-Regulation of S100A8 is an Independent Predictor of PSA Recurrence in Prostate Cancer Treated by Radical Prostatectomy.Neoplasia2019
31606028High-level expression of protein tyrosine phosphatase non-receptor 12 is a strong and independent predictor of poor prognosis in prostate cancer.BMC Cancer2019
31545001A shift from membranous and stromal syndecan-1 (CD138) expression to cytoplasmic CD138 expression is associated with poor prognosis in breast cancer.Mol Carcinog2019
31534629Prognostic and diagnostic role of PSA immunohistochemistry: A tissue microarray study on 21,000 normal and cancerous tissues.Oncotarget2019
29115542IMP3 overexpression occurs in various important cancer types and is linked to aggressive tumor features: A tissue microarray study on 8,877 human cancers and normal tissues.Oncol Rep2018
29803408Up regulation of the steroid hormone synthesis regulator HSD3B2 is linked to early PSA recurrence in prostate cancer.Exp Mol Pathol2018
29908878Marked Prognostic Impact of Minimal Lymphatic Tumor Spread in Prostate Cancer.Eur Urol2018
29855276PSCA expression is associated with favorable tumor features and reduced PSA recurrence in operated prostate cancer.BMC Cancer2018
2992364713q deletion is linked to an adverse phenotype and poor prognosis in prostate cancer.Genes Chromosomes Cancer2018
30322727Aberrant expression of membranous carbonic anhydrase IX (CAIX) is associated with unfavorable disease course in papillary and clear cell renal cell carcinoma.Urol Oncol2018
30519097Upregulation of centromere protein F is linked to aggressive prostate cancers.Cancer Manag Res2018
30419865Reduced RBM3 expression is associated with aggressive tumor features in esophageal cancer but not significantly linked to patient outcome.BMC Cancer2018
30537516Molecular Evolution of Early-Onset Prostate Cancer Identifies Molecular Risk Markers and Clinical Trajectories.Cancer Cell2018
30510458Deletion of 3p13 is a late event linked to progression of <i>TMPRSS2</i>:<i>ERG</i> fusion prostate cancer.Cancer Manag Res2018
30333886High concordance of TMPRSS-ERG fusion between primary prostate cancer and its lymph node metastases.Oncol Lett2018
28117112Integrating Tertiary Gleason 5 Patterns into Quantitative Gleason Grading in Prostate Biopsies and Prostatectomy Specimens.Eur Urol2018
29427004Immunohistochemically detected IDH1<sup>R132H</sup> mutation is rare and mostly heterogeneous in prostate cancer.World J Urol2018
29304771High BCAR1 expression is associated with early PSA recurrence in ERG negative prostate cancer.BMC Cancer2018
27803051Up-regulation of mismatch repair genes MSH6, PMS2 and MLH1 parallels development of genetic instability and is linked to tumor aggressiveness and early PSA recurrence in prostate cancer.Carcinogenesis2017
28415558Family with sequence similarity 13C (FAM13C) overexpression is an independent prognostic marker in prostate cancer.Oncotarget2017
28295933High concordance of findings obtained from transgluteal magnetic resonance imaging - and transrectal ultrasonography-guided biopsy as compared with prostatectomy specimens.BJU Int2017
28467610Apurinic/apyrimidinic endonuclease 1 (APE1/Ref-1) overexpression is an independent prognostic marker in prostate cancer without TMPRSS2:ERG fusion.Mol Carcinog2017
28146062High-Level γ-Glutamyl-Hydrolase (GGH) Expression is Linked to Poor Prognosis in ERG Negative Prostate Cancer.Int J Mol Sci2017
28117928MALDI imaging mass spectrometry reveals multiple clinically relevant masses in colorectal cancer using large-scale tissue microarrays.J Mass Spectrom2017
28143998Correction: Genomic deletion of chromosome 12p is an independent prognostic marker in prostate cancer.Oncotarget2017
29029453PTEN loss detection in prostate cancer: comparison of PTEN immunohistochemistry and PTEN FISH in a large retrospective prostatectomy cohort.Oncotarget2017
29022485Prevalence of βIII-tubulin (TUBB3) expression in human normal tissues and cancers.Tumour Biol2017
29312579Deletion lengthening at chromosomes 6q and 16q targets multiple tumor suppressor genes and is associated with an increasingly poor prognosis in prostate cancer.Oncotarget2017
28929505High-Level Glyoxalase 1 (GLO1) expression is linked to poor prognosis in prostate cancer.Prostate2017
28025079βIII-tubulin overexpression is linked to aggressive tumor features and genetic instability in urinary bladder cancer.Hum Pathol2017
  • 1 - 50 of 83

Recommended Authors

Julie Livingstone
University of California los angeles
Career Start Year 2011
Number of shared co-authors 8
Agnes Marije Hoogland
Erasmus Medical Center
Career Start Year 2011
Number of shared co-authors 2
Adam G Sowalsky
National Cancer Institute
Career Start Year 2010
Number of shared co-authors 2
Kyung Park
New York University Langone Health
Career Start Year 2010
Number of shared co-authors 0
Theresa Y MacDonald
Caryl and Israel Englander Institute for Precision Medicine
Career Start Year 2010
Number of shared co-authors 0
Mohammed Alshalalfa
University of Miami Miller School of Medicine/Sylvester Comprehensive Cancer Center
Career Start Year 2009
Number of shared co-authors 6
Robert J Lonigro
Michigan Center for Translational Pathology, University of Michigan ann arbor
Career Start Year 2007
Number of shared co-authors 0
Verena Sailer
Institute for Pathology, University Hospital Schleswig-Holstein
Career Start Year 2007
Number of shared co-authors 0
Roula Albadine
Centre hospitalier de l'Universite de Montreal
Career Start Year 2006
Number of shared co-authors 3
Michael C Haffner
Fred Hutchinson Cancer Center
Career Start Year 2005
Number of shared co-authors 2
Nening Dennis
Institute of Cancer Research
Career Start Year 2004
Number of shared co-authors 2
Karl-Philippe Gu??rard
McGill University and the Research Institute of the McGill University Health Centre
Career Start Year 2004
Number of shared co-authors 1
Scott A Tomlins
Rogel Cancer Center, University of Michigan Medical School ann arbor
Career Start Year 2003
Number of shared co-authors 2
Christopher E Barbieri
Weill Cornell Medical College
Career Start Year 2003
Number of shared co-authors 1
Tarek A Bismar
University of Calgary Cumming School of Medicine, Rockyview General Hospital
Career Start Year 2002
Number of shared co-authors 3
Juan Miguel Mosquera
Caryl and Israel Englander Institute for Precision Medicine
Career Start Year 2002
Number of shared co-authors 1
David S Rickman
Meyer Cancer Center
Career Start Year 2001
Number of shared co-authors 1
Michael Fraser
Princess Margaret Cancer Centre, University Health Network
Career Start Year 2001
Number of shared co-authors 14
Andrea Sboner
Institute for Computational Biomedicine
Career Start Year 2000
Number of shared co-authors 3
Rohit Mehra
Michigan Center for Translational Pathology.
Career Start Year 2000
Number of shared co-authors 3
Xuhong Cao
Michigan Center for Translational Pathology.
Career Start Year 1999
Number of shared co-authors 1
Yong-Jie Lu
Barts Cancer Institute, Queen Mary University of London
Career Start Year 1993
Number of shared co-authors 8
Arul M Chinnaiyan
University of Michigan Medical School.
Career Start Year 1993
Number of shared co-authors 7
Rosina T Lis
National Cancer Institute
Career Start Year 1992
Number of shared co-authors 1
Gyorgy Petrovics
Henry Jackson Foundation for the Advancement of Military Medicine (HJF)
Career Start Year 1990
Number of shared co-authors 2
Nallasivam Palanisamy
Vattikuti Urology Institute
Career Start Year 1990
Number of shared co-authors 1
Mark A Rubin
University of Bern
Career Start Year 1990
Number of shared co-authors 15
Colin C Collins
University of British Columbia
Career Start Year 1988
Number of shared co-authors 5
Tapio Visakorpi
Prostate Cancer Research Center, Tampere University and Tays Cancer Center
Career Start Year 1987
Number of shared co-authors 5
George Steven Bova
Prostate Cancer Research Center, Tampere University and Tays Cancer Center
Career Start Year 1982
Number of shared co-authors 4

Collaborators

Ronald Simon
Institute of Pathology, University Medical Center Hamburg-Eppendorf
Co-authored papers 78
Guido Sauter
Institute of Pathology, University Medical Center Hamburg-Eppendorf
Co-authored papers 77
Thorsten Schlomm
Charite - University Hospital Berlin
Co-authored papers 59
Claudia Hube-Magg
Institute of Pathology, University Medical Center Hamburg-Eppendorf
Co-authored papers 52
Markus Graefen
University Hospital Frankfurt, Goethe University Frankfurt am Main
Co-authored papers 49
Martina Kluth
Institute of Pathology, University Medical Center Hamburg-Eppendorf
Co-authored papers 48
Hartwig Huland
Martini-Klinik Prostate Cancer Center, University Hospital-Hamburg-Eppendorf
Co-authored papers 39
Joachim Weischenfeldt
University of Copenhagen
Co-authored papers 5
Jan O Korbel
European Bioinformatics Institute (EMBL-EBI)
Co-authored papers 5
Jan Meiners
University Medical Center Hamburg-Eppendorf
Co-authored papers 4
Benedikt Brors
German Cancer Research Center (DKFZ)
Co-authored papers 3
Christoph Plass
German Cancer Research Center
Co-authored papers 3
Hartmut Schl??ter
University Medical Center Hamburg-Eppendorf
Co-authored papers 3
Lars Feuerbach
German Cancer Research Center (DKFZ)
Co-authored papers 2
Yassen Assenov
German Cancer Research Center (DKFZ)
Co-authored papers 2
Derya Tilki
Universitatsklinikum Hamburg-Eppendorf
Co-authored papers 2
Clarissa Gerh??user
German Cancer Research Center (DKFZ)
Co-authored papers 2
Olga Bogatyrova
German Cancer Research Center
Co-authored papers 2
Vyacheslav Amstislavskiy
Max-Planck-Institute for Molecular Genetics
Co-authored papers 1
S??ren Matzk
Max Planck Institute for Molecular Genetics
Co-authored papers 1
Marie-Laure Yaspo
Max Planck Institute for Molecular Genetics
Co-authored papers 1
Francesco Favero
Universita del Piemonte Orientale
Co-authored papers 1
Eva Reisinger
German Cancer Research Center (DKFZ)
Co-authored papers 1
Doreen Heckmann
University Children's Hospital
Co-authored papers 1
Hans-J??rg Warnatz
Max Planck Institute for Molecular Genetics
Co-authored papers 1
Alicia Malewska
UT Southwestern Medical Center
Co-authored papers 1
Daniela Schilling
Technical University of Munich (TUM)
Co-authored papers 1
Robert G Bristow
University of Toronto
Co-authored papers 1
Etsehiwot G Girma
Rigshospitalet, University of Copenhagen
Co-authored papers 1
Dmitry A Gordenin
National Institute of Environmental Health Sciences (NIEHS)
Co-authored papers 1
Release 1.2